Equities Analysts Offer Predictions for Immunic Q2 Earnings

Immunic, Inc. (NASDAQ:IMUX) – Analysts at HC Wainwright dropped their Q2 2026 earnings per share (EPS) estimates for Immunic in a research note issued to investors on Thursday, May 14th. HC Wainwright analyst M. Caufield now expects that the company will earn ($2.41) per share for the quarter, down from their prior forecast of ($2.06). HC Wainwright has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Immunic’s current full-year earnings is ($3.38) per share. HC Wainwright also issued estimates for Immunic’s Q3 2026 earnings at ($2.21) EPS, Q4 2026 earnings at ($2.03) EPS, FY2026 earnings at ($7.02) EPS, FY2027 earnings at ($9.05) EPS, FY2028 earnings at ($5.88) EPS, FY2029 earnings at ($4.51) EPS and FY2030 earnings at ($2.92) EPS.

A number of other analysts have also recently commented on the company. Lifesci Capital upgraded Immunic to a “strong-buy” rating in a research report on Monday, May 4th. Guggenheim started coverage on Immunic in a research report on Tuesday, March 24th. They issued a “buy” rating and a $70.00 price target for the company. D. Boral Capital cut Immunic from a “buy” rating to a “hold” rating in a research report on Wednesday, April 15th. Stifel Nicolaus set a $25.00 price target on Immunic and gave the stock a “buy” rating in a research report on Thursday, April 16th. Finally, Roth Mkm reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Immunic in a research note on Thursday. Three equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Immunic has an average rating of “Buy” and a consensus target price of $50.86.

Immunic Stock Down 3.5%

Shares of IMUX opened at $11.66 on Tuesday. The business has a 50-day simple moving average of $11.45 and a two-hundred day simple moving average of $8.66. The stock has a market cap of $158.81 million, a price-to-earnings ratio of -2.09 and a beta of 1.20. Immunic has a 52 week low of $5.06 and a 52 week high of $15.10.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.37).

Hedge Funds Weigh In On Immunic

A number of hedge funds have recently made changes to their positions in the business. ADAR1 Capital Management LLC bought a new position in shares of Immunic in the first quarter worth about $33,000. Qube Research & Technologies Ltd bought a new position in shares of Immunic in the third quarter worth about $29,000. Focus Partners Wealth boosted its stake in shares of Immunic by 1.5% in the third quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock worth $2,276,000 after acquiring an additional 39,063 shares during the period. Two Sigma Investments LP bought a new position in shares of Immunic in the third quarter worth about $52,000. Finally, Squarepoint Ops LLC boosted its stake in shares of Immunic by 29.9% in the fourth quarter. Squarepoint Ops LLC now owns 352,875 shares of the company’s stock worth $188,000 after acquiring an additional 81,301 shares during the period. Institutional investors own 51.82% of the company’s stock.

Key Stories Impacting Immunic

Here are the key news stories impacting Immunic this week:

• Positive Sentiment: Immunic appointed veteran biopharmaceutical executive Michael W. Bonney as Chair of the Board, a move that may be viewed favorably because of his deep commercialization and leadership experience in multiple sclerosis and biotech. Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
• Neutral Sentiment: Multiple brokerage notes reiterated bullish ratings on Immunic, including HC Wainwright’s Buy rating and $22 price target, which suggests continued long-term optimism despite near-term risk.
• Negative Sentiment: HC Wainwright cut earnings estimates across several future periods, signaling expectations for larger losses than previously modeled. The firm reduced its FY2026 EPS estimate to ($7.02) from ($2.61), FY2027 to ($9.05) from ($6.01), FY2028 to ($5.88) from ($3.66), FY2029 to ($4.51) from ($2.36), and FY2030 to ($2.92) from ($1.08).
• Negative Sentiment: The analyst also lowered quarterly EPS forecasts for Q2 2026, Q3 2026, and Q4 2026, reinforcing concerns that Immunic may burn cash for longer than expected before reaching profitability.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.